SCHEMBL4789684

SCHEMBL4789684

BrCc1cc(-c2ccncc2)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP2C19 P33261 1/20 0.46
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
LMNA P02545 3/20 0.45
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
IDO1 P14902 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
ROCK2 O75116 1/20 0.41
PRKCA P17252 1/20 0.41
GRK2 P25098 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4789134 0.83 CYP2D6 (0.66) CYP2D6CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL4790492 0.83 CYP2D6 (0.45) CYP2D6CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL5096941 0.80 SMN1; SMN2 (0.50) CYP2D6CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL5096712 0.78 CYP11B1 (0.59) CYP2D6CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL27540721 0.76 HCAR2 (0.49) CYP2D6CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL3860074 0.76 L3MBTL1 (0.68) CYP2D6CYP2C9CYP2C19MKNK1MKNK2
SCHEMBL5103933 0.75 CYP11B1 (0.47) CYP2D6CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL14311768 0.75 CYP11B1 (0.57) RAB9ANPC1SMN1; SMN2CYP11B1CYP11B2
SCHEMBL14289624 0.75 MKNK1 (0.41) CYP2D6CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL1602901 0.75 MAPT (0.54) CYP11B1CYP11B2GSK3BMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008011557-A2 HETEROARYL INHIBITORS OF RHO KINASE BORCHARDT ALLEN J (US) 2008-01-24 WO disclosed
WO-2008011557-A2 HETEROARYL INHIBITORS OF RHO KINASE BORCHARDT ALLEN J (US) 2008-01-24 WO disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE ROCK1, ROCK2, RHOA CYP2D6 4480/4885CYP2A6 4361/4885CYP2C9 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.